Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 16/20 | 0.50 |
| ▸ | EDNRB | P24530 | 12/20 | 0.50 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.42 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7217797 | 0.90 | EDNRA (0.54) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| SCHEMBL6150865 | 0.84 | EDNRA (0.54) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| SCHEMBL6152888 | 0.82 | EDNRA (0.48) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| SCHEMBL4631462 | 0.79 | EDNRA (0.53) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| SCHEMBL4631489 | 0.79 | EDNRA (0.53) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| SCHEMBL7014658 | 0.78 | EDNRA (0.55) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| SCHEMBL4631516 | 0.77 | EDNRA (0.53) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| SCHEMBL4663251 | 0.77 | EDNRA (0.50) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| SCHEMBL6151439 | 0.76 | EDNRA (0.48) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| SCHEMBL7212878 | 0.76 | EDNRA (0.53) | EDNRAEDNRBALDH1A1HSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6683103-B2 | SULFONAMIDES CONTAINING OXAZOLE AND SUBSTITUTED THIOPHENE RINGS, USEFUL FOR TREATING HYPERTENSION, CARDIOVASCULAR DISEASE, ASTHMA, PULMONARY HYPERTENSION, INFLAMMATORY DISEASES, VISION DEFECTS, MENSTRUAL DISORDERS, RENAL FAILURE | TEXAS BIOTECHNOLOGY CORPORATION | 2004-01-27 | — | — | US | disclosed |
| US-20020091270-A1 | Sulfonamides for treatment of endothelin-mediated disorders | ENCYSIVE PHARMACEUTICALS INC. | 2002-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091270-A1 | Sulfonamides for treatment of endothelin-mediated disorders | EDNRA, ECE1, EDNRB | EDNRA 1/4885EDNRB 3/4885ABCC3 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.